The Sarepta Duchenne story is anything but boring: what it may tell us about patient voice and biomarkers in gene therapy
In case you missed it, the FDA ad comm for Sarepta’s SRP-9001 Duchenne muscular dystrophy drug candidate was held on Friday, May 12.